Portfolio company
Sightera Biosciences
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Sightera Biosciences develops AI-designed small molecule drugs for pharmaceutical partners and patients with therapy-resistant cancer and fibrosis.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Sightera
Sightera develops an artificial intelligence platform for drug discovery to design small-molecule therapies for oncology and fibrosis patients.
Ten63 Therapeutics
This company develops small-molecule drugs for pharmaceutical partners and patients using a generative artificial intelligence and physics-based chemistry platform to treat undruggable protein targets.
innovothera
This biotechnology company develops small-molecule therapies for fibrosis, inflammatory diseases, and cancer using an artificial intelligence drug discovery platform.
Serna Bio
This company develops an AI-native platform to discover small molecule drugs targeting RNA for pharmaceutical partners treating respiratory and other complex diseases.
Technology-enabled pharmaceutical company
This company develops small molecule drug candidates using artificial intelligence for the pharmaceutical and biotechnology industries.
Auron Therapeutics
This company develops small-molecule drugs using an AI-powered platform to treat patients with cancer and inflammatory diseases.
AI-enabled drug design
This company develops generative machine learning platforms to design and optimise small-molecule drug candidates for pharmaceutical and biotechnology partners.
PharmEnable
This company develops small molecule medicines using an artificial intelligence platform for pharmaceutical partners and patients with oncology and neurology conditions.